Since the silencing of the GSDME gene makes it difficult to induce cancer cell pyrotosis with apoptosis-inducing drugs, and since reduced expression levels of GSDME are associated with poor prognosis in cancer patients, the promoter methylation may be a potential drug target in cancer therapy [30,64]. The gene discussed is GSDME; the disease is cancer.